Cardiovascular

Latest News


Lipoprotein(a) and Cardiovascular Risk

Learn about more about lipoprotein(a), including how to improve patient outcomes through better screening and management.

Lipoprotein(a) and Cardiovascular Risk

Advancements in Population Health Strategies for Cardiovascular Risk Management

Experts discuss how lipoproteins drive atherosclerotic heart disease, review the different guidelines and recommendations on Lp(a) testing, and insights from clinical trials.

Advancements in Population Health Strategies for Cardiovascular Risk Management

Latest Videos


Shorts

Varsha Tanguturi, MD, Mass General
1:34
Exploring Provider Notification in Aortic Stenosis Care: Varsha Tanguturi, MD
11 days ago
by
Maggie L. Shaw(+1 more)
Dr Alexandra M. Trevino
0:47
History of HDP Tied to Chronic Heart, Metabolic Conditions: Alexandra M. Trevino, MD
a month ago
by
Brooke McCormick(+2 more)
Dr Alexandra M. Trevino
0:34
Chronic Illness, Lifestyle, and Social Disparities Fuel HDP Risk: Alexandra M. Trevino, MD
a month ago
by
Brooke McCormick(+2 more)
Khush Kharidia, MD, UT Southwestern
1:02
Partnering on Social Media to Combat Medical Misinformation: Khush Kharidia, MD
a month ago
by
Maggie L. Shaw(+1 more)

Podcasts


CME Content


More News

Experts discuss lessons learned from implementing lipoprotein(a) (Lp[a]) testing in health care systems, how health systems can prioritize patients for testing based on the National Lipid Association’s (NLA) recommendation, the role of integrated delivery networks in helping providers identify priority patients, and strategies for adding electronic health record alerts for Lp(a) testing.

Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its commonality within health plans, and how payers, population health decision makers, and provider groups can integrate Lp(a) testing into broader population health management strategies.

Experts discuss how knowledge of lipoprotein(a) (Lp[a]) levels can empower patients in managing atherosclerotic cardiovascular disease (ASCVD) risk factors, how providers can collaborate with patients on Lp(a) testing and risk management, the potential population-level value of improved ASCVD risk assessment, and how the National Lipid Association’s (NLA) recommendation for one-time Lp(a) testing may benefit health systems.

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo